Cancer Research: The Lessons to Learn from COVID-19
Chris Bailey, James R.M. Black, Charles Swanton
Abstract
The COVID-19 pandemic has caused widespread disruption of cancer clinical trials due to the restrictions on nonessential services and the reallocation of resources, and at the same time the urgent global effort toward discovering therapies that treat or prevent COVID-19 infection has led to shortening of traditional regulatory timelines. This experience should stimulate similar urgency in the way future cancer research is conducted.
Topics & Concepts
PandemicCancerClinical trialMedicineCoronavirus disease 2019 (COVID-19)Intensive care medicineCancer treatmentMEDLINESevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCancer therapyBioinformaticsOncologyCancer drugsClinical researchCOVID-19 and healthcare impactsCOVID-19 Clinical Research StudiesImmune responses and vaccinations